Shield Therapeutics PLC Total Voting Rights Update (1730U)
March 31 2021 - 9:01AM
UK Regulatory
TIDMSTX
RNS Number : 1730U
Shield Therapeutics PLC
31 March 2021
Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
Total Voting Rights Update
London, UK, 31 March 2021: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing
iron deficiency with its lead product Feraccru (R) /Accrufer(R)
(ferric maltol), confirms that in accordance with the requirements
of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's
issued share capital consists of 215,837,965 ordinary shares of
1.5p each in issue, each with equal voting rights. No shares are
held in treasury.
The above figure may also be used by shareholders as the
denominator in the calculations by which they will determine
whether they are required to notify their interest, or a change to
their interest, in the Company under the FCA's Disclosure Guidance
and Transparency Rules.
For further information, please contact:
Shield Therapeutics plc +44 (0) 191 511 8500
Tim Watts (CEO)
Lucy Huntington-Bailey (Company Secretary
and General Counsel) +44 (0)191 511 8500
Peel Hunt LLP - Nominated Adviser & Joint
Broker +44 (0) 20 7148 8900
James Steel / Christopher Golden
finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Alice Lane / Matthew
Radley
Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne or shield@walbrookpr.com
About Shield
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product Feraccru
(R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based
oral therapy for adults with iron deficiency with or without
anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been
approved for use in the United States, European Union, UK and
Switzerland and has exclusive IP rights until the mid-2030s. The
Group plans to launch Accrufer(R) in the US during 2021 through a
highly experienced sales and marketing team. Feraccru(R) is already
being commercialised in the UK and European Union by Norgine B.V.,
who also have the marketing rights in Australia and New Zealand.
Shield also has an exclusive licence agreement with Beijing
Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong,
Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRXFLFXFXLEBBL
(END) Dow Jones Newswires
March 31, 2021 10:01 ET (14:01 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024